Warner Chilcott Holdings, a specialty pharmaceutical company developing and selling branded prescription pharmaceutical products in women’s healthcare and dermatology, announced the terms for its IPO on Tuesday. The offering will consist of 70.6 million shares at a range of $17-$19, which gives the deal a proposed market cap of $4.2 billion. Goldman Sachs, Credit Suisse, JP Morgan and Morgan Stanley are leading the group of underwriters on the deal. Timing has yet to be announced.
